Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bacillus Calmette‐Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I‐deficient tumor cells
Rafael Carretero, Teresa Cabrera, Hernani Gil, et al.
International Journal of Cancer (2010) Vol. 129, Iss. 4, pp. 839-846
Open Access | Times Cited: 55

Showing 26-50 of 55 citing articles:

Future Directions in Bladder Cancer Immunotherapy: Towards Adaptive Immunity
Sean G. Smith, David A. Zaharoff
Immunotherapy (2016) Vol. 8, Iss. 3, pp. 351-365
Open Access | Times Cited: 31
Immunotherapy eradicates metastases with reversible defects in MHC class I expression
Cristina Garrido, Irene Gallego Romero, Enrique Berruguilla, et al.
Cancer Immunology Immunotherapy (2011) Vol. 60, Iss. 9, pp. 1257-1268
Open Access | Times Cited: 33
Changing the Tumor Microenvironment: New Strategies for Immunotherapy
Pedro Berraondo, Viktor Umansky, Ignacio Melero
Cancer Research (2012) Vol. 72, Iss. 20, pp. 5159-5164
Open Access | Times Cited: 29
Investigating T Cell Immunity in Cancer: Achievements and Prospects
Zhen Zeng, Hui Yi Chew, Jazmina L. G. Cruz, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 6, pp. 2907-2907
Open Access | Times Cited: 20
Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives
Hiroshi Kitamura, Taiji Tsukamoto
Cancers (2011) Vol. 3, Iss. 3, pp. 3055-3072
Open Access | Times Cited: 25
The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review
Lasse Lindholm Johansen, Jørgen Lock‐Andersen, Thomas Vauvert F. Hviid
Journal of Immunology Research (2016) Vol. 2016, pp. 1-11
Open Access | Times Cited: 21
Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of HLA Class I Alterations in Cancer
María Antonia Garrido, Francisco Perea, José R. Vilchez, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5046-5046
Open Access | Times Cited: 17
Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes
Hernani Gil-Julio, Francisco Perea, Antonio Rodríguez-Nicolás, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7248-7248
Open Access | Times Cited: 16
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
Evan Rosenbaum, Rashmi Chugh, Christopher W. Ryan, et al.
European Journal of Cancer (2022) Vol. 176, pp. 155-163
Open Access | Times Cited: 12
Expression of sialyl-Tn sugar antigen in bladder cancer cells affects response to Bacillus Calmette Guérin (BCG) and to oxidative damage
Paulo F. Severino, Mariana Silva, Mylène A. Carrascal, et al.
Oncotarget (2017) Vol. 8, Iss. 33, pp. 54506-54517
Open Access | Times Cited: 19
A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer
José Francisco Flores-Martín, Francisco Perea, Manuela Expósito Ruíz, et al.
Annals of Surgical Oncology (2019) Vol. 26, Iss. 8, pp. 2631-2639
Closed Access | Times Cited: 19
MHC Class I Regulation: The Origin Perspective
Alicja Sznarkowska, Sara Mikac, Magdalena Pilch
Cancers (2020) Vol. 12, Iss. 5, pp. 1155-1155
Open Access | Times Cited: 16
Bacillus Calmette-Guérin Induces Cellular Reactive Oxygen Species and Lipid Peroxidation in Cancer Cells
Juwita N. Rahmat, Kesavan Esuvaranathan, Ratha Mahendran
Urology (2012) Vol. 79, Iss. 6, pp. 1411.e15-1411.e20
Closed Access | Times Cited: 15
Oxidative damage and response to Bacillus Calmette-Guérin in bladder cancer cells expressing sialyltransferase ST3GAL1
Paulo F. Severino, Mariana Silva, Mylène A. Carrascal, et al.
BMC Cancer (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 14
Effect of HLA genotype on intravesical recurrence after bacillus Calmette–Guérin therapy for non-muscle-invasive bladder cancer
Mizuki Kobayashi, Nobuhiro Fujiyama, Tokiyoshi Tanegashima, et al.
Cancer Immunology Immunotherapy (2021) Vol. 71, Iss. 3, pp. 727-736
Closed Access | Times Cited: 11
Conflicting HLA assignment by three different typing methods due to the apparent loss of heterozygosity in the MHC region
Tiina Linjama, Ulla Impola, Riitta Niittyvuopio, et al.
HLA (2016) Vol. 87, Iss. 5, pp. 350-355
Closed Access | Times Cited: 8
Recurrent bladder cancer in aging societies: Importance of major histocompatibility complex class I antigen presentation
Edyta Wieczorek, Malgorzata Garstka
International Journal of Cancer (2020) Vol. 148, Iss. 8, pp. 1808-1820
Open Access | Times Cited: 6
Haploidentical hematopoietic stem cell transplantation for lymphoma with monosomy of chromosome 6 (loss of heterozygosity in the HLA region) — Who should be a donor?
Kazuhiro Ikegame, Katsuji Kaida, Leif Lakoma, et al.
Transplant Immunology (2012) Vol. 27, Iss. 4, pp. 162-165
Closed Access | Times Cited: 5
Implicación de las moléculas HLA de clase I en el escape inmunitario de tumores urológicos
Rafael Carretero, Hernani Gil-Julio, Fernando Vázquez‐Alonso, et al.
Actas Urológicas Españolas (2013) Vol. 38, Iss. 3, pp. 192-199
Closed Access | Times Cited: 3
New approaches to vaccines for cancer
Vivek P. Chavda, Devarshi Acharya, Saloni Malla, et al.
Elsevier eBooks (2024), pp. 357-390
Closed Access
MHC/HLA Class-I Loss and Cancer Immune Escape
Federico Garrido
Springer eBooks (2024), pp. 63-90
Closed Access
Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities
María Antonia Garrido, Alba Navarro-Ocón, Víctor Ronco-Díaz, et al.
Genes (2024) Vol. 15, Iss. 12, pp. 1542-1542
Open Access
Involvement of HLA class I molecules in the immune escape of urologic tumors
Rafael Carretero, Hernani Gil-Julio, Fernando Vázquez‐Alonso, et al.
Actas Urológicas Españolas (English Edition) (2014) Vol. 38, Iss. 3, pp. 192-199
Closed Access | Times Cited: 2
A Vaccine against Cancer: Can There Be a Possible Strategy to Face the Challenge? Possible Targets and Paradoxical Effects
Roberto Zefferino, Massimo Conese
Vaccines (2023) Vol. 11, Iss. 11, pp. 1701-1701
Open Access | Times Cited: 1
Intravesical BCG: where do we stand? Past, present and future
Catherine Hobbs, Edward Bass, Jeremy Crew, et al.
Journal of Clinical Urology (2019) Vol. 12, Iss. 6, pp. 425-435
Closed Access | Times Cited: 2

Scroll to top